[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.234.223.162. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
1.
National Center for Health Statistics.  Health, United States, 2015. Hyattsville, MD: Centers for Disease Control and Prevention; 2016.
2.
Hart  RG, Pearce  LA, Aguilar  MI.  Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.  Ann Intern Med. 2007;146(12):857-867.PubMedGoogle ScholarCrossref
3.
Baigent  C, Blackwell  L, Collins  R,  et al; Antithrombotic Trialists’ (ATT) Collaboration.  Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.  Lancet. 2009;373(9678):1849-1860.PubMedGoogle ScholarCrossref
4.
Shehab  N, Lovegrove  MC, Geller  AI, Rose  KO, Weidle  NJ, Budnitz  DS.  US emergency department visits for outpatient adverse drug events, 2013-2014.  JAMA. 2016;316(20):2115-2125.PubMedGoogle ScholarCrossref
5.
Budnitz  DS, Lovegrove  MC, Shehab  N, Richards  CL.  Emergency hospitalizations for adverse drug events in older Americans.  N Engl J Med. 2011;365(21):2002-2012.PubMedGoogle ScholarCrossref
6.
Ruff  CT, Giugliano  RP, Braunwald  E,  et al.  Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.  Lancet. 2014;383(9921):955-962.PubMedGoogle ScholarCrossref
7.
Gaist  D, García Rodríguez  LA, Hellfritzsch  M,  et al.  Association of antithrombotic drug use with subdural hematoma risk.  JAMA. 2017;317(8):836-846.PubMedGoogle ScholarCrossref
8.
Culclasure  TF, Bray  VJ, Hasbargen  JA.  The significance of hematuria in the anticoagulated patient.  Arch Intern Med. 1994;154(6):649-652.PubMedGoogle ScholarCrossref
9.
Matulewicz  RS, Meeks  JJ.  Blood in the urine (hematuria).  JAMA. 2016;316(14):1508.PubMedGoogle ScholarCrossref
10.
von Elm  E, Altman  DG, Egger  M, Pocock  SJ, Gøtzsche  PC, Vandenbroucke  JP; STROBE Initiative.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.  Ann Intern Med. 2007;147(8):573-577.PubMedGoogle ScholarCrossref
11.
Benchimol  EI, Smeeth  L, Guttmann  A,  et al; RECORD Working Committee.  The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement.  PLoS Med. 2015;12(10):e1001885.PubMedGoogle ScholarCrossref
12.
Ontario's Local Health Integration Networks. http://www.lhins.on.ca/. Accessed March 17, 2017.
13.
Johns Hopkins Bloomberg School of Public Health.  The Johns Hopkins ACG Case-Mix System Reference Manual Version 7.0. Baltimore, MD: The Johns Hopkins University Bloomberg School of Public Health; 2005.
14.
Austin  PC, van Walraven  C, Wodchis  WP, Newman  A, Anderson  GM.  Using the Johns Hopkins Aggregated Diagnosis Groups (ADGs) to predict mortality in a general adult population cohort in Ontario, Canada.  Med Care. 2011;49(10):932-939.PubMedGoogle ScholarCrossref
15.
Levy  AR, O’Brien  BJ, Sellors  C, Grootendorst  P, Willison  D.  Coding accuracy of administrative drug claims in the Ontario Drug Benefit database.  Can J Clin Pharmacol. 2003;10(2):67-71.PubMedGoogle Scholar
16.
Juurlink  DN, Preyra  C, Croxford  R,  et al.  Canadian Institute for Health Information Discharge Abstract Database: A Validation Study. Toronto, ON, Canada: Institute for Clinical Evaluation Sciences; 2006.
17.
Williams  JI, Young  W. A summary of studies on the quality of health care administrative databases in Canada. In: Goel  V, Williams  J, Anderson  G,  et al, eds.  Patterns of Health Care in Ontario, Canada: The ICES Practice Atlas. Ottawa, ON, Canada: Canadian Medical Association; 1996:339-345.
18.
Robles  SC, Marrett  LD, Clarke  EA, Risch  HA.  An application of capture-recapture methods to the estimation of completeness of cancer registration.  J Clin Epidemiol. 1988;41(5):495-501.PubMedGoogle ScholarCrossref
19.
Iron  K, Zagorski  BM, Sykora  K, Manuel  DG.  Living and Dying in Ontario: An Opportunity for Improved Health Information. Toronto, ON, Canada: ICES Investigative Report; 2008.
20.
Diehr  P, Yanez  D, Ash  A, Hornbrook  M, Lin  DY.  Methods for analyzing health care utilization and costs.  Annu Rev Public Health. 1999;20:125-144.PubMedGoogle ScholarCrossref
21.
Moineddin  R, Meaney  C, Agha  M, Zagorski  B, Glazier  RH.  Modeling factors influencing the demand for emergency department services in Ontario: a comparison of methods.  BMC Emerg Med. 2011;11:13.PubMedGoogle ScholarCrossref
22.
Vasdev  N, Kumar  A, Veeratterapillay  R, Thorpe  AC.  Hematuria secondary to benign prostatic hyperplasia: retrospective analysis of 166 men identified in a single one stop hematuria clinic.  Curr Urol. 2013;6(3):146-149.PubMedGoogle ScholarCrossref
23.
Moreno  JA, Martín-Cleary  C, Gutiérrez  E,  et al.  Haematuria: the forgotten CKD factor?  Nephrol Dial Transplant. 2012;27(1):28-34.PubMedGoogle ScholarCrossref
24.
Yao  X, Abraham  NS, Sangaralingham  LR,  et al.  Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation.  J Am Heart Assoc. 2016;5(6):e003725.PubMedGoogle ScholarCrossref
25.
Larsen  TB, Skjøth  F, Nielsen  PB, Kjældgaard  JN, Lip  GY.  Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.  BMJ. 2016;353:i3189.PubMedGoogle ScholarCrossref
26.
Mariani  AJ, Mariani  MC, Macchioni  C, Stams  UK, Hariharan  A, Moriera  A.  The significance of adult hematuria: 1,000 hematuria evaluations including a risk-benefit and cost-effectiveness analysis.  J Urol. 1989;141(2):350-355.PubMedGoogle ScholarCrossref
27.
Avidor  Y, Nadu  A, Matzkin  H.  Clinical significance of gross hematuria and its evaluation in patients receiving anticoagulant and aspirin treatment.  Urology. 2000;55(1):22-24.PubMedGoogle ScholarCrossref
28.
Gomes  T, Mamdani  MM, Holbrook  AM, Paterson  JM, Hellings  C, Juurlink  DN.  Rates of hemorrhage during warfarin therapy for atrial fibrillation.  CMAJ. 2013;185(2):E121-E127.PubMedGoogle ScholarCrossref
29.
Chai-Adisaksopha  C, Crowther  M, Isayama  T, Lim  W.  The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis.  Blood. 2014;124(15):2450-2458.PubMedGoogle ScholarCrossref
30.
Holster  IL, Valkhoff  VE, Kuipers  EJ, Tjwa  ET.  New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis.  Gastroenterology. 2013;145(1):105-112.e15.PubMedGoogle ScholarCrossref
31.
Martinelli  I, Lensing  AW, Middeldorp  S,  et al.  Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use.  Blood. 2016;127(11):1417-1425.PubMedGoogle ScholarCrossref
32.
Adelborg  K, Grove  EL, Sundbøll  J, Laursen  M, Schmidt  M.  Sixteen-year nationwide trends in antithrombotic drug use in Denmark and its correlation with landmark studies.  Heart. 2016;102(23):1883-1889.PubMedGoogle ScholarCrossref
33.
Groninger  H, Phillips  JM.  Gross hematuria: assessment and management at the end of life.  J Hosp Palliat Nurs. 2012;14(3):184-188.PubMedGoogle ScholarCrossref
34.
Raparelli  V, Proietti  M, Cangemi  R, Lip  GY, Lane  DA, Basili  S.  Adherence to oral anticoagulant therapy in patients with atrial fibrillation: focus on non-vitamin K antagonist oral anticoagulants.  Thromb Haemost. 2017;117(2):209-218.PubMedGoogle ScholarCrossref
35.
Jackevicius  CA, Tsadok  MA, Essebag  V,  et al.  Early non-persistence with dabigatran and rivaroxaban in patients with atrial fibrillation.  Heart. 2017;103(17):1331-1338.PubMedGoogle ScholarCrossref
36.
Sengupta  N, Feuerstein  JD, Patwardhan  VR,  et al.  The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a prospective study.  Am J Gastroenterol. 2015;110(2):328-335.PubMedGoogle ScholarCrossref
37.
Maura  G, Blotière  PO, Bouillon  K,  et al.  Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.  Circulation. 2015;132(13):1252-1260.PubMedGoogle ScholarCrossref
38.
Yu  J, Mehran  R, Dangas  GD,  et al.  Safety and efficacy of high- versus low-dose aspirin after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial.  JACC Cardiovasc Interv. 2012;5(12):1231-1238.PubMedGoogle ScholarCrossref
39.
Huang  ES, Strate  LL, Ho  WW, Lee  SS, Chan  AT.  Long-term use of aspirin and the risk of gastrointestinal bleeding.  Am J Med. 2011;124(5):426-433.PubMedGoogle ScholarCrossref
40.
Rodriguez  RA, Carrier  M, Wells  PS.  Non-adherence to new oral anticoagulants: a reason for concern during long-term anticoagulation?  J Thromb Haemost. 2013;11(2):390-394.PubMedGoogle ScholarCrossref
Original Investigation
October 3, 2017

Association Between Use of Antithrombotic Medication and Hematuria-Related Complications

Author Affiliations
  • 1Division of Urology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
  • 2Institute for Health Policy, Management & Evaluation, University of Toronto, Toronto, Ontario, Canada
  • 3Department of Medicine, St Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada
  • 4Division of Urology, University Health Network, University of Toronto, Toronto, Ontario, Canada
  • 5Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
  • 6Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada
JAMA. 2017;318(13):1260-1271. doi:10.1001/jama.2017.13890
Key Points

Question  Is there an association between the use of oral antithrombotic agents and hematuria-related complications?

Findings  In this cohort study that included 2 518 064 older adults in Ontario, Canada, use of antithrombotic medications, compared with nonuse of these medications, was significantly associated with hematuria-related complications (including emergency department visits, hospitalizations, and urologic procedures).

Meaning  Use of antithrombotic medications was associated with a significant increase in rates of hematuria-related complications.

Abstract

Importance  Antithrombotic medications are among the most commonly prescribed medications.

Objective  To characterize rates of hematuria-related complications among patients taking antithrombotic medications.

Design, Setting, and Participants  Population-based, retrospective cohort study including all citizens in Ontario, Canada, aged 66 years and older between 2002 and 2014. The final follow-up date was December 31, 2014.

Exposures  Receipt of an oral anticoagulant or antiplatelet medication.

Main Outcomes and Measures  Hematuria-related complications, defined as emergency department visit, hospitalization, or a urologic procedure to investigate or manage gross hematuria.

Results  Among 2 518 064 patients, 808 897 (mean [SD] age, 72.1 [6.8] years; 428 531 [53%] women) received at least 1 prescription for an antithrombotic agent over the study period. Over a median follow-up of 7.3 years, the rates of hematuria-related complications were 123.95 events per 1000 person-years among patients actively exposed to antithrombotic agents vs 80.17 events per 1000 person-years among patients not exposed to these drugs (difference, 43.8; 95% CI, 43.0-44.6; P < .001, and incidence rate ratio [IRR], 1.44; 95% CI, 1.42-1.46). The rates of complications among exposed vs unexposed patients (80.17 events/1000 person-years) were 105.78 for urologic procedures (difference, 33.5; 95% CI, 32.8-34.3; P < .001, and IRR, 1.37; 95% CI, 1.36-1.39), 11.12 for hospitalizations (difference, 5.7; 95% CI, 5.5-5.9; P < .001, and IRR, 2.03; 95% CI, 2.00-2.06), and 7.05 for emergency department visits (difference, 4.5; 95% CI, 4.3-4.7; P < .001, and IRR, 2.80; 95% CI, 2.74-2.86). Compared with patients who were unexposed to thrombotic agents, the rates of hematuria-related complications were 191.61 events per 1000 person-years (difference, 117.3; 95% CI, 112.8-121.8) for those exposed to both an anticoagulant and antiplatelet agent (IRR, 10.48; 95% CI, 8.16-13.45), 140.92 (difference, 57.7; 95% CI, 56.9-58.4) for those exposed to anticoagulants (IRR, 1.55; 95% CI, 1.52-1.59), and 110.72 (difference, 26.5; 95% CI, 25.9-27.0) for those exposed to antiplatelet agents (IRR, 1.31; 95% CI, 1.29-1.33). Patients exposed to antithrombotic agents, compared with patients not exposed to these drugs, were more likely to be diagnosed as having bladder cancer within 6 months (0.70% vs 0.38%; odds ratio, 1.85; 95% CI, 1.79-1.92).

Conclusions and Relevance  Among older adults in Ontario, Canada, use of antithrombotic medications, compared with nonuse of these medications, was significantly associated with higher rates of hematuria-related complications (including emergency department visits, hospitalizations, and urologic procedures to manage gross hematuria).

×